Shirish Hirani
Nessuna posizione attualmente
Profilo
Shirish Hirani worked as Vice President of Drug Development at ARIAD Pharmaceuticals, Inc. from 2005 to 2017.
Prior to that, he held the same position at Transkaryotic Therapies, Inc. from 2002 to 2005 and was Senior Vice President of Product Development at Dyax Corp.
from 1997 to 2002.
He also served as SVP of Program Management & Product Planning at ArQule, Inc. Dr. Hirani received his undergraduate and doctorate degrees from Queen Elizabeth College.
Precedenti posizioni note di Shirish Hirani
| Società | Posizione | Fine |
|---|---|---|
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/04/2017 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Corporate Officer/Principal | 01/01/2005 |
| DYAX CORP. | Corporate Officer/Principal | 01/01/2002 |
| ARQULE, INC. | Corporate Officer/Principal | - |
Formazione di Shirish Hirani
| Queen Elizabeth College | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
- Borsa valori
- Insiders
- Shirish Hirani
